XML 46 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Research and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 18 Months Ended
Jun. 30, 2015
USD ($)
May 31, 2014
USD ($)
Oct. 31, 2011
USD ($)
item
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2013
USD ($)
Research and License Agreements                
Research and Development Expense       $ 5,722,070 $ 5,781,176 $ 11,600,578 $ 11,299,898  
License Agreement | Pfizer                
Research and License Agreements                
Milestone revenue       0 0 $ 0 0  
License Agreement | Pfizer | Up-Front Payment Arrangement                
Research and License Agreements                
Upfront payment received     $ 22,500,000          
Upfront payment revenue recognized               $ 22,500,000
Recognition period of up-front payment               1 year 6 months
Research Services Agreement | University Of Basel                
Research and License Agreements                
Royalty payment due against license fees received (as a percent)           10.00%    
Milestone payment obligation       $ 0 $ 0 $ 0 $ 0  
Achievement Of Specified Development Milestone | License Agreement | Pfizer                
Research and License Agreements                
Milestone revenue $ 20,000,000 $ 15,000,000            
Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum                
Research and License Agreements                
Potential milestone payments     $ 115,000,000          
Number of indications | item     2          
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum                
Research and License Agreements                
Potential milestone payments     $ 70,000,000          
Number of indications | item     2          
Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum                
Research and License Agreements                
Potential milestone payments     $ 135,000,000